AbClon Inc

AbClon Inc maintains a strong liquidity position with cash and equivalents amounting to 39,010,866,040 KRW, representing 55.1% of total assets. The company's liquidity FPT (free cash flow to total assets) is negative at -24.87%, indicating ongoing cash outflows from operations. The current ratio of 4.92 suggests robust short-term liquidity, with current assets significantly exceeding current liabilities. Profitability metrics are negative, with a return on equity of -29.63% and a return on assets of -25.31%. These figures are well below the industry median for biotechnology firms, which typically range between 5% and 15% for ROE and 8% to 12% for ROA. The company reported a net loss of 17,906,959,740 KRW, driven by a significant operating loss of 17,635,733,970 KRW. Geographically, AbClon Inc's revenue is concentrated in South Korea, with no material international revenue disclosed in the latest financials. The company operates in a single business segment focused on monoclonal antibody therapeutics, with no diversification across product lines or geographic regions. Growth trajectory is mixed. While the company's latest reported revenue of 4,714,084,170 KRW is in line with analyst estimates of 2,757,000,000 KRW, the operating cash flow of -13,828,783,950 KRW and free cash flow of -17,594,822,340 KRW indicate ongoing operational challenges. The capital expenditure of -617,642,880 KRW suggests continued investment in R&D and infrastructure. Risk factors include a low liquidity risk score and a low dilution risk score. The company has no immediate filing-based liquidity or dilution flags, and the debt-to-equity ratio of 0.12 indicates a conservative capital structure with minimal leverage. Recent events include the continued development of its lead candidate, which is in Phase III clinical trials for oncology applications. No material regulatory or litigation events were disclosed in the latest filings. The company has not issued new shares in the past 12 months, and no ATM or shelf registration is currently active.